AG˹ٷ

STOCK TITAN

[8-K] MIRA Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

MGIC Investment Corp. (MTG) � Form 4 insider transaction

President & COO Salvatore A. Miosi disclosed the sale of 30,000 shares of common stock on 01-Jul-2025 at a weighted-average price of $28.152 per share, generating roughly $0.84 million in proceeds. The disposition was executed under a Rule 10b5-1 trading plan adopted on 06-Mar-2025, indicating the sale was pre-scheduled and not necessarily driven by near-term information.

After the transaction, Miosi directly owns 279,401.361 shares and indirectly controls 384,844 shares via a family trust, maintaining a sizable equity stake. No derivative security activity was reported, and the filing contains no references to earnings, major corporate events, or strategic changes.

The filing primarily records a routine adjustment to the executive’s equity exposure; in isolation, it is unlikely to materially affect the company’s fundamental outlook.

MGIC Investment Corp. (MTG) � Transazione interna Form 4

Il Presidente e COO Salvatore A. Miosi ha comunicato la vendita di 30.000 azioni ordinarie il 01-lug-2025 a un prezzo medio ponderato di $28,152 per azione, generando circa $0,84 milioni di proventi. La cessione è stata effettuata nell'ambito di un piano di trading Rule 10b5-1 adottato il 06-mar-2025, indicando che la vendita era programmata in anticipo e non necessariamente motivata da informazioni a breve termine.

Dopo la transazione, Miosi possiede direttamente 279.401,361 azioni e controlla indirettamente 384.844 azioni tramite un trust familiare, mantenendo una quota azionaria significativa. Non sono state segnalate attività su strumenti derivati e il deposito non fa riferimento a utili, eventi aziendali rilevanti o cambiamenti strategici.

Il deposito registra principalmente un aggiustamento di routine nell'esposizione azionaria dell'esecutivo; isolatamente, è improbabile che influisca materialmente sulle prospettive fondamentali della società.

MGIC Investment Corp. (MTG) � Transacción interna Formulario 4

El Presidente y COO Salvatore A. Miosi informó la venta de 30,000 acciones ordinarias el 01-jul-2025 a un precio promedio ponderado de $28.152 por acción, generando aproximadamente $0.84 millones en ingresos. La venta se realizó bajo un plan de negociación Rule 10b5-1 adoptado el 06-mar-2025, lo que indica que la operación fue programada con anticipación y no necesariamente motivada por información a corto plazo.

Tras la transacción, Miosi posee directamente 279,401.361 acciones y controla indirectamente 384,844 acciones a través de un fideicomiso familiar, manteniendo una participación accionaria significativa. No se reportaron actividades con valores derivados y el informe no menciona ganancias, eventos corporativos importantes ni cambios estratégicos.

El informe registra principalmente un ajuste rutinario en la exposición accionaria del ejecutivo; aisladamente, es poco probable que afecte materialmente la perspectiva fundamental de la empresa.

MGIC Investment Corp. (MTG) � Form 4 내부� 거래

사장 � COO 살바토레 A. 미오시는 2025� 7� 1일에 30,000� 보통�� 주당 가중평� 가� $28.152� 매도했으�, � $0.84백만� 수익� 창출했습니다. � 매도� 2025� 3� 6일에 채택� Rule 10b5-1 거래 계획� 따라 실행되어, 매도가 사전� 예정� 것이� 단기 정보� 의해 반드� 이루어진 것은 아님� 나타냅니�.

거래 � 미오시는 직접적으� 279,401.361�� 보유하고 있으�, 가� 신탁� 통해 간접적으� 384,844�� 통제하여 상당� 지분을 유지하고 있습니다. 파생상품 관� 활동은 보고되지 않았�, 제출 문서에는 수익, 주요 기업 사건 또는 전략� 변화에 대� 언급� 없습니다.

� 제출 문서� 주로 임원� 지� 노출� 대� 일상적인 조정 사항� 기록� 것으�, 단독으로 회사� 근본적인 전망� 실질적인 영향� 미칠 가능성은 낮습니다.

MGIC Investment Corp. (MTG) � Transaction d'initié Formulaire 4

Le Président et COO Salvatore A. Miosi a déclaré la vente de 30 000 actions ordinaires le 01-juil-2025 au prix moyen pondéré de 28,152 $ par action, générant environ 0,84 million de dollars de produit. La cession a été réalisée dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 06-mar-2025, indiquant que la vente était programmée à l'avance et non nécessairement motivée par des informations à court terme.

Après la transaction, Miosi détient directement 279 401,361 actions et contrôle indirectement 384 844 actions via une fiducie familiale, conservant une participation importante. Aucune activité sur des dérivés n'a été signalée et le dépôt ne fait référence ni aux bénéfices, ni à des événements majeurs de l'entreprise, ni à des changements stratégiques.

Le dépôt enregistre principalement un ajustement de routine de l'exposition en actions de l'exécutif ; isolément, il est peu probable qu'il affecte de manière significative les perspectives fondamentales de la société.

MGIC Investment Corp. (MTG) � Form 4 Insider-Transaktion

Präsident & COO Salvatore A. Miosi meldete den Verkauf von 30.000 Stammaktien am 01. Juli 2025 zu einem gewichteten Durchschnittspreis von 28,152 $ pro Aktie, was etwa 0,84 Mio. $ Erlös einbrachte. Die Veräußerung erfolgte im Rahmen eines Rule 10b5-1 Handelsplans, der am 06. März 2025 angenommen wurde, was darauf hinweist, dass der Verkauf vorab geplant war und nicht unbedingt durch kurzfristige Informationen motiviert wurde.

Nach der Transaktion besitzt Miosi direkt 279.401,361 Aktien und kontrolliert indirekt 384.844 Aktien über einen Familientrust, womit er eine bedeutende Beteiligung hält. Es wurden keine Aktivitäten mit Derivaten gemeldet, und die Einreichung enthält keine Hinweise auf Gewinne, bedeutende Unternehmensereignisse oder strategische Veränderungen.

Die Einreichung dokumentiert hauptsächlich eine routinemäßige Anpassung der Aktienexposition des Geschäftsführers; isoliert betrachtet wird dies die fundamentale Perspektive des Unternehmens voraussichtlich nicht wesentlich beeinflussen.

Positive
  • Sale executed under a Rule 10b5-1 plan, reducing concerns about opportunistic insider trading.
  • Executive retains significant ownership�279,401 direct and 384,844 indirect shares—maintaining alignment with shareholders.
Negative
  • Disposition of 30,000 shares by the President & COO represents a cash realisation of roughly $0.84 million.
  • Direct ownership dilution may be interpreted by some investors as a mildly negative sentiment signal.

Insights

TL;DR Pre-planned 30k-share sale by MTG COO is modest and leaves large stake; overall market impact neutral.

The transaction represents approximately 4�5 % of the executive’s combined direct and indirect holdings. Because it was carried out under a Rule 10b5-1 plan, the signalling value is limited. Proceeds of roughly $0.84 million suggest personal diversification rather than a statement on valuation. With no derivative activity or concurrent corporate news, I view the filing as routine and not a catalyst for valuation change.

TL;DR Scheduled sale aligns with governance best practices; minor share reduction poses low governance risk.

Utilising a pre-established 10b5-1 plan mitigates concerns about selective disclosure or opportunistic trading and demonstrates compliance discipline. The officer still holds over 660k shares, maintaining strong alignment with shareholder interests. From a governance perspective, the event is non-problematic and should not influence proxy advisory stances.

MGIC Investment Corp. (MTG) � Transazione interna Form 4

Il Presidente e COO Salvatore A. Miosi ha comunicato la vendita di 30.000 azioni ordinarie il 01-lug-2025 a un prezzo medio ponderato di $28,152 per azione, generando circa $0,84 milioni di proventi. La cessione è stata effettuata nell'ambito di un piano di trading Rule 10b5-1 adottato il 06-mar-2025, indicando che la vendita era programmata in anticipo e non necessariamente motivata da informazioni a breve termine.

Dopo la transazione, Miosi possiede direttamente 279.401,361 azioni e controlla indirettamente 384.844 azioni tramite un trust familiare, mantenendo una quota azionaria significativa. Non sono state segnalate attività su strumenti derivati e il deposito non fa riferimento a utili, eventi aziendali rilevanti o cambiamenti strategici.

Il deposito registra principalmente un aggiustamento di routine nell'esposizione azionaria dell'esecutivo; isolatamente, è improbabile che influisca materialmente sulle prospettive fondamentali della società.

MGIC Investment Corp. (MTG) � Transacción interna Formulario 4

El Presidente y COO Salvatore A. Miosi informó la venta de 30,000 acciones ordinarias el 01-jul-2025 a un precio promedio ponderado de $28.152 por acción, generando aproximadamente $0.84 millones en ingresos. La venta se realizó bajo un plan de negociación Rule 10b5-1 adoptado el 06-mar-2025, lo que indica que la operación fue programada con anticipación y no necesariamente motivada por información a corto plazo.

Tras la transacción, Miosi posee directamente 279,401.361 acciones y controla indirectamente 384,844 acciones a través de un fideicomiso familiar, manteniendo una participación accionaria significativa. No se reportaron actividades con valores derivados y el informe no menciona ganancias, eventos corporativos importantes ni cambios estratégicos.

El informe registra principalmente un ajuste rutinario en la exposición accionaria del ejecutivo; aisladamente, es poco probable que afecte materialmente la perspectiva fundamental de la empresa.

MGIC Investment Corp. (MTG) � Form 4 내부� 거래

사장 � COO 살바토레 A. 미오시는 2025� 7� 1일에 30,000� 보통�� 주당 가중평� 가� $28.152� 매도했으�, � $0.84백만� 수익� 창출했습니다. � 매도� 2025� 3� 6일에 채택� Rule 10b5-1 거래 계획� 따라 실행되어, 매도가 사전� 예정� 것이� 단기 정보� 의해 반드� 이루어진 것은 아님� 나타냅니�.

거래 � 미오시는 직접적으� 279,401.361�� 보유하고 있으�, 가� 신탁� 통해 간접적으� 384,844�� 통제하여 상당� 지분을 유지하고 있습니다. 파생상품 관� 활동은 보고되지 않았�, 제출 문서에는 수익, 주요 기업 사건 또는 전략� 변화에 대� 언급� 없습니다.

� 제출 문서� 주로 임원� 지� 노출� 대� 일상적인 조정 사항� 기록� 것으�, 단독으로 회사� 근본적인 전망� 실질적인 영향� 미칠 가능성은 낮습니다.

MGIC Investment Corp. (MTG) � Transaction d'initié Formulaire 4

Le Président et COO Salvatore A. Miosi a déclaré la vente de 30 000 actions ordinaires le 01-juil-2025 au prix moyen pondéré de 28,152 $ par action, générant environ 0,84 million de dollars de produit. La cession a été réalisée dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 06-mar-2025, indiquant que la vente était programmée à l'avance et non nécessairement motivée par des informations à court terme.

Après la transaction, Miosi détient directement 279 401,361 actions et contrôle indirectement 384 844 actions via une fiducie familiale, conservant une participation importante. Aucune activité sur des dérivés n'a été signalée et le dépôt ne fait référence ni aux bénéfices, ni à des événements majeurs de l'entreprise, ni à des changements stratégiques.

Le dépôt enregistre principalement un ajustement de routine de l'exposition en actions de l'exécutif ; isolément, il est peu probable qu'il affecte de manière significative les perspectives fondamentales de la société.

MGIC Investment Corp. (MTG) � Form 4 Insider-Transaktion

Präsident & COO Salvatore A. Miosi meldete den Verkauf von 30.000 Stammaktien am 01. Juli 2025 zu einem gewichteten Durchschnittspreis von 28,152 $ pro Aktie, was etwa 0,84 Mio. $ Erlös einbrachte. Die Veräußerung erfolgte im Rahmen eines Rule 10b5-1 Handelsplans, der am 06. März 2025 angenommen wurde, was darauf hinweist, dass der Verkauf vorab geplant war und nicht unbedingt durch kurzfristige Informationen motiviert wurde.

Nach der Transaktion besitzt Miosi direkt 279.401,361 Aktien und kontrolliert indirekt 384.844 Aktien über einen Familientrust, womit er eine bedeutende Beteiligung hält. Es wurden keine Aktivitäten mit Derivaten gemeldet, und die Einreichung enthält keine Hinweise auf Gewinne, bedeutende Unternehmensereignisse oder strategische Veränderungen.

Die Einreichung dokumentiert hauptsächlich eine routinemäßige Anpassung der Aktienexposition des Geschäftsführers; isoliert betrachtet wird dies die fundamentale Perspektive des Unternehmens voraussichtlich nicht wesentlich beeinflussen.

false 0001904286 0001904286 2025-07-02 2025-07-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 2, 2025

 

MIRA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Florida   001-41765   85-3354547
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

1200 Brickell Avenue, Suite 1950 #1183
Miami, Florida 33131
(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (786) 432-9792

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   MIRA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 8.01 Other Events

 

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

 

On July 2, 2025, MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”) announced preclinical results demonstrating that its proprietary drug candidate, Mira-55, a non-psychoactive marijuana analog, delivered morphine-comparable pain relief in a validated animal model of inflammatory pain, without inducing local inflammation.

 

Mira-55 is a synthetic analog of marijuana engineered to selectively activate CB2 receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, it exhibits minimal activity at CB1 receptors, thus avoiding psychoactive side effects. In a formalin-based rodent model, Mira-55 significantly reduced pain sensitivity, restored pain thresholds to near-baseline levels, and showed efficacy comparable to morphine, the opioid control. No sedative or inflammatory effects were observed.

 

In addition, the Company previously received confirmation from the U.S. Drug Enforcement Administration (DEA) that Mira-55 is not classified as a controlled substance, removing a key regulatory barrier to clinical development.

 

These new results strengthen MIRA’s pain-focused pipeline by positioning Mira-55 as a complementary program to Ketamir-2, the Company’s clinical-stage NMDA receptor antagonist currently progressing through Phase 1 development for neuropathic pain.

 

“With Mira-55 and Ketamir-2, we believe we’re building a differentiated, non-opioid pain franchise with the potential to treat two of the largest and most underserved pain markets,” said Erez Aminov, Chairman and CEO of MIRA.

 

MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings—highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction.

 

MIRA continues to advance Mira-55 toward an Investigational New Drug (IND) submission, with development efforts supporting future clinical trials in inflammatory pain indications.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MIRA PHARMACEUTICALS, INC.
   
Dated: July 2, 2025 By: /s/ Erez Aminov
  Name:  Erez Aminov                                           
  Title: Chief Executive Officer

 

 

 

FAQ

How many MGIC (MTG) shares did President & COO Salvatore Miosi sell on 1 Jul 2025?

He sold 30,000 shares of MGIC common stock.

At what price were the MTG shares sold according to the Form 4?

The weighted-average sale price was $28.152 per share, with trades ranging from $27.80 to $28.34.

What trading plan covered the MTG insider sale disclosed on July 1, 2025?

The sale was executed under a Rule 10b5-1 trading plan adopted on 06-Mar-2025.

How many MGIC shares does Salvatore Miosi own after the transaction?

He owns 279,401.361 shares directly and 384,844 shares indirectly through a family trust.

Is any derivative security activity reported in this MTG Form 4?

No derivative securities were acquired or disposed of; Table II is blank.

When was the Rule 10b5-1 plan adopted by the MTG executive?

The plan was adopted on 06-Mar-2025.
Mira Pharma

NASDAQ:MIRA

MIRA Rankings

MIRA Latest News

MIRA Latest SEC Filings

MIRA Stock Data

20.47M
13.59M
23.68%
6.61%
4.26%
Drug Manufacturers - General
Pharmaceutical Preparations
United States
MIAMI